Oral activated charcoal adsorbent (AST-120) ameliorates extent and instability of atherosclerosis accelerated by kidney disease in apolipoprotein E-deficient mice
Open accessThe DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Accelerated atherosclerosis and increased cardiovascular events are not only more common in chronic kidney disease (CKD) but are more resistant to therapeutic interventions effective in the general population. The oral charcoal adsorbent, AST-120, currently used to delay start of dialysis, reduces circulating and tissue uremic toxins, which may contribute to vasculopathy, including atherosclerosis. We, therefore, investigated whether AST-120 affects CKD-induced atherosclerosis. METHODS: Apolipoprotein E-deficient mice, a model of atherosclerosis, underwent uninephrectomy, subtotal nephrectomy or sham operation at 8 weeks of age and were treated with AST-120 after renal ablation. Atherosclerosis and its characteristics were assessed at 25 weeks of age. RESULTS: Uninephrectomy and subtotal nephrectomised mice had significantly increased acceleration of atherosclerosis. AST-120 treatment dramatically reduced the atherosclerotic burden in mice with kidney damage, while there was no beneficial effect in sham-operated mice. The benefit was independent of blood pressure, serum total cholesterol or creatinine clearance. AST-120 significantly decreased necrotic areas and lessened aortic deposition of the uremic toxin indoxyl sulfate without affecting lesional macrophage or collagen content. Furthermore, AST-120 lessened aortic expression of monocyte chemoattractant protein-1, tumor necrosis factor-α and interleukin-1β messenger RNA. CONCLUSIONS: AST-120 lessens the extent of atherosclerosis induced by kidney injury and alters lesion characteristics in apolipoprotein E-deficient mice, resulting in plaques with a more stable phenotype with less necrosis and reduced inflammation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“in animal models of renal dysfunction, the oral charcoal absorbent AST-120 significantly decreased necrotic areas and lessened aortic deposition of the uremic toxin indoxyl sulfate without affecting lesional macrophage or collagen content (73) while attenuating monocyte inflammation (74).”
From The contributory role of gut microbiota in cardiovascular disease (2014) · cites this paper as [73]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674 · cited 1×
“Recent interest in lipid-independent risk predictors has identified inflammation as an important contributor to CVD in the general population [24, 25].”
BackgroundInflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., & Hennekens, C. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361401 · Cited by 5,504
Sarnak, M. J., Levey, A. S., Schoolwerth, A. C., Coresh, J., Culleton, B., Hamm, L. L., McCullough, P. A., Kasiske, B. L., Kelepouris, E., Klag, M. J., et al. (2003) · Circulation · doi:10.1161/01.cir.0000095676.90936.80 · Cited by 3,768 · cited 2×
“CKD dramatically increases atherosclerosis and cardiovascular events [1, 2].”
BackgroundRosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641
Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis
Fellström, B. C., Jardine, A. G., Schmieder, R. E., Holdaas, H., Bannister, K., Beutler, J., Chae, D.-W., Chevaile, A., Cobbe, S. M., Grönhagen-Riska, C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810177 · Cited by 2,036 · cited 2×
“also the most resistant to conventional lipid-lowering therapies [5].”
BackgroundKeith, D. S., Nichols, G. A., Gullion, C. M., Brown, J. B., & Smith, D. H. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.6.659 · Cited by 1,684 · cited 1×
“Indeed, the risk of premature cardiovascular disease (CVD) death in patients with CKD is much higher than the risk of progressing to dialysis or transplantation [3, 4].”
BackgroundInflammatory Markers and the Risk of Coronary Heart Disease in Men and Women
Pai, J. K., Pischon, T., Ma, J., Manson, J. E., Hankinson, S. E., Joshipura, K., Curhan, G. C., Rifai, N., Cannuscio, C. C., Stampfer, M. J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040967 · Cited by 1,174 · cited 1×
“Recent interest in lipid-independent risk predictors has identified inflammation as an important contributor to CVD in the general population [24, 25].”
BackgroundSelf-citationSarnak, M. J., Levey, A. S., Schoolwerth, A. C., Coresh, J., Culleton, B., Hamm, L. L., McCullough, P. A., Kasiske, B. L., Kelepouris, E., Klag, M. J., et al. (2003) · Hypertension · doi:10.1161/01.hyp.0000102971.85504.7c · Cited by 1,144
Barreto, F. C., Barreto, D. V., Liabeuf, S., Meert, N., Glorieux, G., Temmar, M., Choukroun, G., Vanholder, R., & Massy, Z. A. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03980609 · Cited by 929 · cited 3×
“clinical findings showing that serum indoxyl sulfate is correlated with cardiovascular mortality in CKD patients [15] and that CKD patients treated with AST-120 before initiation of dialysis have significantly better 5-year survival after dialysis was begun compared with patients who did not receive this treatment bef…”
BackgroundResultInfluentialMenon, V., Greene, T., Wang, X., Pereira, A. A., Marcovina, S. M., Beck, G. J., Kusek, J. W., Collins, A. J., Levey, A. S., & Sarnak, M. J. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00455.x · Cited by 417 · cited 1×
“This mechanism may be an especially relevant predictor of cardiovascular mortality at every stage of CKD [26, 27].”
BackgroundThorp, E., Cui, D., Schrijvers, D. M., Kuriakose, G., & Tabas, I. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.167197 · Cited by 357 · cited 2×
“Increased necrosis and apoptosis linked to reduced efferocytosis were also noted in atherosclerotic lesions of mice reconstituted with macrophages defective in the tyrosine kinase Mertk receptor [33].”
BackgroundMethodFinn, A. V., Kolodgie, F. D., & Virmani, R. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.173609 · Cited by 350 · cited 1×
“Plaque composition is a crucial component of risk for acute coronary events, as vulnerable plaques have increased inflammatory cytokines, expanded necrotic areas, induced a focal decrease in collagen deposition and are prone to rupture and thrombosis [37].”
BackgroundCardiovascular Disease and Subsequent Kidney Disease
Elsayed, E. F., Tighiouart, H., Griffith, J., Kurth, T., Levey, A. S., Salem, D., Sarnak, M. J., & Weiner, D. E. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.11.1130 · Cited by 255 · cited 2×
“CKD dramatically increases atherosclerosis and cardiovascular events [1, 2].”
BackgroundModel of robust induction of glomerulosclerosis in mice: Importance of genetic background
Ma, L.-J., & Fogo, A. B. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00058.x · Cited by 246 · cited 1×
“Although BP tended to increase in mice with the most severe renal ablation, there was no significant difference among the groups as expected in these mice with C57BL/6 background, a strain resistant to development of glomerulosclerosis and hypertension following renal ablation [22].”
BackgroundSelf-citationTumur, Z., Shimizu, H., Enomoto, A., Miyazaki, H., & Niwa, T. (2010) · American Journal of Nephrology · doi:10.1159/000299798 · Cited by 246 · cited 1×
“In vitro , in-doxyl sulfate was recently shown to be associated with upregulation in oxidative stress-mediated increased mRNA expression of intercellular adhesion molecule-1 (ICAM-1) and MCP-1 [31].”
BackgroundIncreased atherosclerosis in LDL receptor–null mice lacking ACAT1 in macrophages
Fazio, S., Major, A. S., Swift, L. L., Gleaves, L. A., Accad, M., Linton, M. F., & Farese, R. V. (2001) · Journal of Clinical Investigation · doi:10.1172/jci10310 · Cited by 243 · cited 5×
“Serum total cholesterol and triglyceride levels were determined at the end of the experiment as previously described [17, 18].”
MethodInfluentialSelf-citationTakahashi, A., Takase, H., Toriyama, T., Sugiura, T., Kurita, Y., Ueda, R., & Dohi, Y. (2006) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfl293 · Cited by 206 · cited 1×
“Since ARB therapy is a mainstay of CVD therapy in the general population and reduces atherosclerosis in experimental CKD as well as cardiovascular morbidity and mortality in hemodialysis patients [42, 43], it is possible that the combination of an ARB and AST-120 may be of particular benefit in reducing CVD in CKD.”
BackgroundUremia Accelerates both Atherosclerosis and Arterial Calcification in Apolipoprotein E Knockout Mice
Massy, Z. A., Ivanovski, O., Nguyen-Khoa, T., Angulo, J., Szumilak, D., Mothu, N., Phan, O., Daudon, M., Lacour, B., Dru[Combining Diaeresis]eke, T. B., et al. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004060495 · Cited by 203 · cited 1×
“Differences between these results and previous reports describing vascular calcification in nephrectomized mice [39–41] may reflect more severe kidney dysfunction, differences relating to the method of renal ablation and/or difference in diet composition, which could affect levels of vitamin D, calcium and phosphate,…”
ResultSchulman, G., Agarwal, R., Acharya, M., Berl, T., Blumenthal, S., & Kopyt, N. (2006) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.12.036 · Cited by 200 · cited 3×
“Although AST-120 has currently not been shown to decrease incidence of doubling of serum creatinine in humans [13], a Phase 3 clinical trial is underway to examine its effects on the composite end point of serum creatinine elevation or progression to transplant or dialysis [9].”
BackgroundSuzuki, H., Kanno, Y., Sugahara, S., Ikeda, N., Shoda, J., Takenaka, T., Inoue, T., & Araki, R. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.04.031 · Cited by 191 · cited 1×
“Since ARB therapy is a mainstay of CVD therapy in the general population and reduces atherosclerosis in experimental CKD as well as cardiovascular morbidity and mortality in hemodialysis patients [42, 43], it is possible that the combination of an ARB and AST-120 may be of particular benefit in reducing CVD in CKD.”
BackgroundThe association of sudden cardiac death with inflammation and other traditional risk factors
Parekh, R. S., Plantinga, L. C., Kao, W. H. L., Meoni, L. A., Jaar, B. G., Fink, N. E., Powe, N. R., Coresh, J., & Klag, M. J. (2008) · Kidney International · doi:10.1038/ki.2008.449 · Cited by 181 · cited 1×
“This mechanism may be an especially relevant predictor of cardiovascular mortality at every stage of CKD [26, 27].”
BackgroundIndoxyl Sulfate Induces Leukocyte-Endothelial Interactions through Up-regulation of E-selectin
Ito, S., Osaka, M., Higuchi, Y., Nishijima, F., Ishii, H., & Yoshida, M. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.166686 · Cited by 177
Chronic Renal Failure Accelerates Atherogenesis in Apolipoprotein E–Deficient Mice
Bro, S., Bentzon, J. F., Falk, E., Andersen, C. B., Olgaard, K., & Nielsen, L. B. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000088024.72216.2e · Cited by 170 · cited 1×
“Serum total cholesterol was significantly higher in SNx than in UNx and in Sham as previously noted [23].”
ResultMacrophage LRP-1 Controls Plaque Cellularity by Regulating Efferocytosis and Akt Activation
Yancey, P. G., Blakemore, J., Ding, L., Fan, D., Overton, C. D., Zhang, Y., Linton, M. F., & Fazio, S. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.109.202051 · Cited by 168 · cited 1×
“Assessments of necrotic areas have been applied to characterize advanced lesions in mice with intact kidneys [20, 33–35].”
MethodSelf-citationMiyazaki, T., Aoyama, I., Ise, M., Seo, H., & Niwa, T. (2000) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/15.11.1773 · Cited by 160 · cited 5×
“AST-120 delayed progression of CKD, at least in part due to suppression of inflammation in experimental models [10–12].”
BackgroundMethodInfluentialAkizawa, T., Asano, Y., Morita, S., Wakita, T., Onishi, Y., Fukuhara, S., Gejyo, F., Matsuo, S., Yorioka, N., & Kurokawa, K. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2009.05.011 · Cited by 158 · cited 1×
“Although AST-120 has currently not been shown to decrease incidence of doubling of serum creatinine in humans [13], a Phase 3 clinical trial is underway to examine its effects on the composite end point of serum creatinine elevation or progression to transplant or dialysis [9].”
BackgroundSeimon, T. A., Wang, Y., Han, S., Senokuchi, T., Schrijvers, D. M., Kuriakose, G., Tall, A. R., & Tabas, I. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37262 · Cited by 154 · cited 3×
“Necrotic areas were calculated from the ratio of acellular/anuclear areas to total atherosclerotic lesion as previously described [20].”
BackgroundMethodSevelamer Prevents Uremia-Enhanced Atherosclerosis Progression in Apolipoprotein E–Deficient Mice
Phan, O., Ivanovski, O., Nguyen-Khoa, T., Mothu, N., Angulo, J., Westenfeld, R., Ketteler, M., Meert, N., Maizel, J., Nikolov, I. G., et al. (2005) · Circulation · doi:10.1161/circulationaha105.541854 · Cited by 148 · cited 1×
“Differences between these results and previous reports describing vascular calcification in nephrectomized mice [39–41] may reflect more severe kidney dysfunction, differences relating to the method of renal ablation and/or difference in diet composition, which could affect levels of vitamin D, calcium and phosphate,…”
ResultFujii, H., Nishijima, F., Goto, S., Sugano, M., Yamato, H., Kitazawa, R., Kitazawa, S., & Fukagawa, M. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp007 · Cited by 142 · cited 1×
“In this connection, AST-120, an oral charcoal adsorbent that reduces circulating and tissue uremic toxins, delays progression of experimental and human CKD [8, 10–12] at least in part, by suppressing inflammation [10, 11, 28].”
BackgroundIvanovski, O., Szumilak, D., Nguyen‐Khoa, T., Ruellan, N., Phan, O., Lacour, B., Descamps‐Latscha, B., Dreeke, T. B., & Massy, Z. A. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00332.x · Cited by 125 · cited 4×
“It is interesting that in addition to AST-120, other interventions have been shown to benefit renal injury-associated atherosclerosis, including ARBs [29] and inhibitor of oxidant stress and inflammation [38].”
BackgroundInfluentialFocused Atorvastatin Therapy in Managed-Care Patients With Coronary Heart Disease and CKD
Koren, M. J., Davidson, M. H., Wilson, D. J., Fayyad, R. S., Zuckerman, A., & Reed, D. P. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.11.025 · Cited by 115
Indoxyl Sulfate Reduces Superoxide Scavenging Activity in the Kidneys of Normal and Uremic Rats
Owada, S., Goto, S., Bannai, K., Hayashi, H., Nishijima, F., & Niwa, T. (2007) · American Journal of Nephrology · doi:10.1159/000112823 · Cited by 114 · cited 1×
“Urine indoxyl sulfate was measured by HPLC as described previously [19].”
MethodWestenfeld, R., Schäfer, C., Smeets, R., Brandenburg, V. M., Floege, J., Ketteler, M., & Jahnen‐Dechent, W. (2007) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfm094 · Cited by 111 · cited 1×
“Calcium deposition was stained by von Kossa as previously described [21].”
MethodPlasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury
Ma, J., Weisberg, A. D., Griffin, J. P., Vaughan, D. E., Fogo, A. B., & Brown, N. J. (2006) · Kidney International · doi:10.1038/sj.ki.5000201 · Cited by 99 · cited 1×
“, Apex, NC) automated tail cuff as previously described [16].”
MethodSelf-citationAST-120 Treatment in Pre-Dialysis Period Affects the Prognosis in Patients on Hemodialysis
Ueda, H., Shibahara, N., Takagi, S., Inoue, T., & Katsuoka, Y. (2008) · Renal Failure · doi:10.1080/08860220802356531 · Cited by 88 · cited 2×
“Interestingly, AST-120 treatment was observed to lessen all-cause mortality after initiation of hemodialysis [14].”
BackgroundOwada, A., Nakao, M., Koike, J., Ujiie, K., Tomita, K., & Shiigai, T. (1997) · PubMed · Cited by 87
Therapeutic Effects of Oral Sorbent in Undialyzed Uremia
Sanaka, T., Sugino, N., Teraoka, S., & Ota, K. (1988) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(88)80002-7 · Cited by 70 · cited 1×
“Modulation of these accumulating substances in humans with renal disease has been achieved by the oral charcoal adsorbent, AST-120 [7, 8].”
BackgroundAyabe, N., Babaev, V. R., Tang, Y., Tanizawa, T., Fogo, A. B., Linton, M. F., Ichikawa, I., Fazio, S., & Kon, V. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.05.016 · Cited by 59 · cited 4×
“Ten-micrometer-thick cryosections were cut from the proximal aorta beginning at the end of the aortic sinus with modifications specific for computer analysis [17, 18].”
MethodInfluentialSelf-citationAoyama, I., Shimokata, K., & Niwa, T. (2002) · The Nephron journals/Nephron journals · doi:10.1159/000064108 · Cited by 59 · cited 1×
“In this connection, AST-120, an oral charcoal adsorbent that reduces circulating and tissue uremic toxins, delays progression of experimental and human CKD [8, 10–12] at least in part, by suppressing inflammation [10, 11, 28].”
BackgroundPhan, O., Ivanovski, O., Nikolov, I. G., Joki, N., Maizel, J., Louvet, L., Chasseraud, M., Nguyen‐Khoa, T., Lacour, B., Drüeke, T. B., et al. (2007) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfm699 · Cited by 58 · cited 1×
“Differences between these results and previous reports describing vascular calcification in nephrectomized mice [39–41] may reflect more severe kidney dysfunction, differences relating to the method of renal ablation and/or difference in diet composition, which could affect levels of vitamin D, calcium and phosphate,…”
ResultAn Oral Adsorbent, AST-120, Suppresses Oxidative Stress in Uremic Rats
Nakagawa, N., Hasebe, N., Sumitomo, K., Fujino, T., Fukuzawa, J., Hirayama, T., & Kikuchi, K. (2006) · American Journal of Nephrology · doi:10.1159/000096423 · Cited by 52 · cited 3×
“In this connection, AST-120, an oral charcoal adsorbent that reduces circulating and tissue uremic toxins, delays progression of experimental and human CKD [8, 10–12] at least in part, by suppressing inflammation [10, 11, 28].”
BackgroundMethodRenal Dysfunction Potentiates Foam Cell Formation by Repressing ABCA1
Zuo, Y., Yancey, P., Castro, I., Khan, W., Motojima, M., Ichikawa, I., Fogo, A. B., Linton, M. F., Fazio, S., & Kon, V. (2009) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.109.188995 · Cited by 39 · cited 4×
“ARBs have also been shown to modulate macrophage infiltration and lipid homeostasis in arterial foam cells [29, 36].”
BackgroundInfluentialSelf-citationSpontaneous Atherothrombosis and Medial Degradation in Apoe −/− , Npc1 −/− Mice
Welch, C. L., Sun, Y., Arey, B. J., Lemaitre, V., Sharma, N., Ishibashi, M., Sayers, S., Li, R., Gorelik, A., Pleskac, N., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.701276 · Cited by 39 · cited 1×
“Assessments of necrotic areas have been applied to characterize advanced lesions in mice with intact kidneys [20, 33–35].”
MethodSuganuma, E., Babaev, V. R., Motojima, M., Zuo, Y., Ayabe, N., Fogo, A. B., Ichikawa, I., Linton, M. F., Fazio, S., & Kon, V. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006090967 · Cited by 39 · cited 8×
“Previously, we showed that changes in the lipid content and composition, macrophage infiltration, collagen content and elastin integrity were affected by the stage of the lesion and treatment interventions [29, 30, 36].”
BackgroundInfluentialSelf-citationAntiatherogenic Effects of Angiotensin Receptor Antagonism in Mild Renal Dysfunction
Suganuma, E., Zuo, Y., Ayabe, N., Ma, J., Babaev, V. R., Linton, M. F., Fazio, S., Ichikawa, I., Fogo, A. B., & Kon, V. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005080883 · Cited by 32 · cited 12×
“It is interesting that in addition to AST-120, other interventions have been shown to benefit renal injury-associated atherosclerosis, including ARBs [29] and inhibitor of oxidant stress and inflammation [38].”
BackgroundInfluentialSelf-citation
Cited by
Tang, W. H. W., Wang, Z., Fan, Y., Levison, B., Hazen, J. E., Donahue, L. M., Wu, Y., & Hazen, S. L. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.02.617 · Cited by 681
“In the setting of advanced renal diseases, direct binders have been reported to reduce levels of indoxyl sulfate, a tryptophan-based gut microbiome metabolite that has shown antiatherosclerotic effects in animal models (23).”
The contributory role of gut microbiota in cardiovascular disease
Tang, W. H. W., & Hazen, S. L. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72331 · Cited by 641
“…(72), and in animal models of renal dysfunction, the oral charcoal absorbent AST-120 significantly decreased necrotic areas and lessened aortic deposition of the uremic toxin indoxyl sulfate without affecting lesional macrophage or collagen content (73) while attenuating monocyte inflammation (74).”
BackgroundZhang, L. S., & Davies, S. S. (2016) · Genome Medicine · doi:10.1186/s13073-016-0296-x · Cited by 500
“The oral charcoal adsorbent AST-120 binds indoles in the gut lumen and reduces plasma IndS levels, thereby reducing kidney damage and atherosclerosis associated with kidney injury [143].”
BackgroundLim, Y. J., Sidor, N. A., Tonial, N. C., Che, A., & Urquhart, B. L. (2021) · Toxins · doi:10.3390/toxins13020142 · Cited by 373
“In vivo, AST-120 has shown reno- and cardio-protective effects against uremic toxins [60,61].”
BackgroundAtherosclerosis in Chronic Kidney Disease: More, Less, or Just Different?
Valdivielso, J. M., Rodríguez-Puyol, D., Pascual, J., Barrios, C., Bermúdez-López, M., Sánchez-Niño, M. D., Pérez-Fernández, M., & Ortiz, A. (2019) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.312705 · Cited by 305
Metadata
- Authors
- Yamamoto, S., Zuo, Y., Ma, J., Yancey, P. G., Hunley, T. E., Motojima, M., Fogo, A. B., Linton, M. F., Fazio, S., Ichikawa, I., & Kon, V.
- Affiliations
- Vanderbilt University Medical Center (US)
- Tokai University (JP)
- ORCID
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-01-18
- Volume
- 26
- Issue
- 8
- Pages
- 2491-2497
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- PMC
- PMC3203394
- OpenAlex
- W2112575385
- Cited by
- 74
- References
- 46
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 5 · 2023: 4 · 2022: 3 · 2021: 2 · 2020: 8 · 2019: 6 · 2018: 5 · 2017: 2 · 2016: 6 · 2015: 6 · 2014: 10 · 2013: 4 · 2012: 5
- FWCI
- 2.98
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nephrology Dialysis Transplantation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL057986, R01HL087061)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK 44757, U24DK059637, DK59637-01, P50DK044757)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- AST-120, atherosclerosis, chronic kidney disease, uremic toxins, indoxyl sulfate, ApoE-deficient mice, unilateral nephrectomy, subtotal nephrectomy, plaque stability, plaque necrosis, vascular inflammation, MCP-1, TNF-α, IL-1β
- MeSH terms
- Administration, Oral, Animals, Apolipoproteins E, Carbon, Charcoal, Female, Immunoenzyme Techniques, Kidney Diseases, Kidney Function Tests, Mice, Inbred C57BL, Oxides, RNA, Messenger, Tumor Necrosis Factor-alpha, Mice, Knockout, Chemokine CCL2, Reverse Transcriptase Polymerase Chain Reaction, Atherosclerosis, Mice, Interleukin-1beta
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.